Does Blue Cross Blue Shield Cover NovoLog?

How BCBS Formulary Coverage Works for NovoLog

Blue Cross Blue Shield is a federation of 34 independent, locally operated companies, and each one maintains its own prescription drug formulary 1. That means "BCBS covers NovoLog" is both true and incomplete. Your specific affiliate (Anthem, CareFirst, Highmark, Premera, etc.) determines the tier, copay, and any utilization management rules attached to insulin aspart.

NovoLog (insulin aspart) received FDA approval in 2000 as a rapid-acting insulin analog for mealtime glucose control in type 1 and type 2 diabetes 2. The American Diabetes Association (ADA) 2024 Standards of Care list rapid-acting analogs as preferred mealtime insulins for most patients on basal-bolus regimens 3. Because rapid-acting insulin is standard-of-care, BCBS plans almost universally include at least one rapid-acting analog on formulary. The question is whether NovoLog is the preferred product or whether your plan steers you toward Humalog (insulin lispro) or a biosimilar instead.

A 2023 analysis published in Diabetes Care found that formulary restrictions on insulin products increased between 2016 and 2021, with 68% of commercial plans applying some form of utilization management to at least one rapid-acting insulin 4. Patients on BCBS plans should verify coverage annually because formulary changes at renewal can shift NovoLog from Tier 2 to Tier 3 (or vice versa) without notice.

What Tier Is NovoLog on BCBS Plans?

Most BCBS affiliates place NovoLog on Tier 2 (preferred brand) or Tier 3 (non-preferred brand), with copays varying accordingly. Tier 2 copays typically run $30 to $60 per 30-day supply, while Tier 3 copays can reach $75 to $150 5. The tier assignment depends on the rebate agreements each BCBS affiliate negotiates with Novo Nordisk and competing manufacturers.

Some affiliates have moved insulin lispro (Humalog or its authorized generics) to Tier 1 or preferred brand status, pushing NovoLog to a higher tier. An internal formulary review by Anthem BCBS for plan year 2024, for example, listed Humalog as Tier 2 preferred and NovoLog as Tier 3 non-preferred in several commercial plans. This pattern is not universal. CareFirst BCBS and some regional Blues affiliates treat NovoLog as the preferred rapid-acting analog.

To check your plan's current tier placement, call the number on the back of your BCBS card or log into your member portal. The formulary lookup tool shows the tier, quantity limits, and any prior authorization flags for NovoLog vials and pens separately. Pen devices often carry a higher copay than vials because of the added device cost, even though the insulin inside is identical 6.

Prior Authorization and Step Therapy Requirements

Some BCBS affiliates require prior authorization (PA) for NovoLog, particularly when it is classified as non-preferred. PA means your prescribing clinician must submit clinical documentation showing that NovoLog is medically necessary before the plan will cover it 7.

Step therapy is a related restriction. Under step therapy, the plan requires you to try a lower-cost insulin first. The "first step" is usually NPH insulin (an older intermediate-acting insulin) or the plan's preferred rapid-acting analog. If you experience inadequate glycemic control or adverse effects on the step-therapy drug, your clinician can submit a step-therapy exception.

The ADA has formally opposed step therapy for insulin, stating that "insulin therapy should be individualized and not subject to non-medical switching" 8. A 2021 study in JAMA Internal Medicine found that non-medical switching of insulin products was associated with a 21% increase in hypoglycemic events during the 90-day transition period (N=14,720) 9. If your BCBS plan imposes step therapy on NovoLog, your physician can cite this evidence in an exception request.

NovoLog Coverage Under BCBS Medicare Advantage Plans

If you have a BCBS Medicare Advantage plan with Part D prescription drug coverage, NovoLog is covered under the Part D benefit. The Inflation Reduction Act (IRA) of 2022 capped insulin copays at $35 per month for Medicare Part D enrollees, effective January 2023 10. This cap applies to all covered insulin products, including NovoLog vials and pens.

The $35 cap applies during all phases of Part D coverage, including the deductible phase and the coverage gap (formerly the "donut hole"). Before the IRA, some Medicare beneficiaries faced insulin costs exceeding $200 per month in the coverage gap. A CMS analysis estimated the cap would save the average insulin-using Medicare beneficiary $500 per year 10.

For BCBS Medicare Advantage plans specifically, confirm that NovoLog is on your plan's Part D formulary. Some BCBS Medicare plans prefer Humalog or biosimilar insulin lispro, placing NovoLog on a higher tier. The $35 cap still applies regardless of tier, but higher-tier placement can affect coverage if the plan requires PA or step therapy 11.

NovoLog on ACA Marketplace BCBS Plans

BCBS plans sold through the Affordable Care Act (ACA) marketplace must comply with essential health benefit (EHB) requirements, which include prescription drug coverage. Each state's EHB benchmark plan determines the minimum formulary standards 12. Most benchmark plans include at least one rapid-acting insulin analog.

However, "at least one" does not guarantee NovoLog. Some ACA marketplace BCBS plans cover only Humalog or a biosimilar as the preferred rapid-acting option. If NovoLog is non-preferred or excluded, your endocrinologist can request a formulary exception based on clinical need. Common clinical justifications include documented hypoglycemia on alternative insulins, allergy to excipients in competing products, or optimal A1c control on NovoLog specifically.

A 2022 study in Annals of Internal Medicine reported that 29% of ACA marketplace plans imposed quantity limits on rapid-acting insulins, restricting patients to 10 mL (one vial) per 30-day fill regardless of clinical need 13. Patients using insulin pumps or high-dose regimens frequently exceed this quantity. If your BCBS ACA plan restricts NovoLog quantity, request a quantity override by having your clinician document your total daily insulin dose.

How NovoLog Compares to Alternatives on BCBS Formularies

Three rapid-acting insulin analogs compete for BCBS formulary placement: NovoLog (insulin aspart), Humalog (insulin lispro), and Apidra (insulin glulisine). Their clinical efficacy profiles are nearly identical. A Cochrane systematic review of 57 randomized controlled trials (N=16,985) found no clinically meaningful differences in A1c reduction or hypoglycemia rates among the three rapid-acting analogs 14.

The practical difference is price and formulary position. Humalog's authorized generic (Insulin Lispro Injection) launched at a list price 50% below brand Humalog, and many BCBS plans now place it on Tier 1 or Tier 2. Novo Nordisk responded by offering authorized generic insulin aspart (marketed as RebelionPAQ in some channels), but availability is inconsistent 15.

Biosimilar insulin options have expanded since FDA finalized the interchangeability pathway for biologics 1. The FDA approved insulin aspart biosimilars that can be substituted at the pharmacy level in states that allow biosimilar interchangeability. BCBS plans are increasingly adding these biosimilars at preferred-tier copays, making them a cost-effective alternative to brand NovoLog. Ask your pharmacist whether a lower-cost interchangeable insulin aspart product is available on your BCBS plan.

How to Lower Your NovoLog Cost on BCBS

Even with BCBS coverage, insulin costs can strain household budgets. A CDC analysis found that the average annual out-of-pocket insulin expenditure for commercially insured U.S. adults was $493 in 2022, with the top quartile spending over $1,000 16. Several strategies can reduce your NovoLog costs.

Novo Nordisk Patient Assistance Program (PAP). Eligible uninsured or underinsured patients can receive NovoLog at no cost. Income thresholds typically require household earnings below 400% of the federal poverty level 17.

Manufacturer copay cards. Novo Nordisk offers copay savings cards for commercially insured patients, reducing the per-fill copay to as little as $25. These cards do not apply to government-sponsored insurance (Medicare, Medicaid, TRICARE).

Formulary exception requests. If your BCBS plan covers NovoLog at Tier 3 but your clinician documents clinical reasons for preferring it over the Tier 2 alternative, the plan may grant a Tier 2 exception, lowering your copay.

Pharmacy choice. BCBS plans with preferred pharmacy networks offer lower copays at in-network pharmacies. Mail-order pharmacies often provide 90-day supplies at the cost of two copays instead of three, saving 33% on a per-fill basis.

State insulin price cap laws. As of 2024, 25 states and the District of Columbia have enacted insulin copay caps ranging from $25 to $100 per 30-day supply for state-regulated commercial plans 18. If your BCBS plan is state-regulated (not a self-funded employer plan), your state's cap applies to NovoLog.

Clinical Profile of NovoLog: What Your Plan Is Covering

NovoLog (insulin aspart) is a recombinant DNA-origin insulin analog with an onset of action of 10 to 20 minutes after subcutaneous injection, peak activity at 1 to 3 hours, and a duration of 3 to 5 hours 2. It is FDA-approved for type 1 diabetes (adults and children aged 2 years and older) and type 2 diabetes in adults.

The key trial for NovoLog approval demonstrated non-inferiority to regular human insulin, with a mean A1c reduction of 0.15% greater than regular insulin over 24 weeks (P=0.02, N=882) 2. More relevant in practice: rapid-acting analogs reduce postprandial glucose excursions by approximately 20 mg/dL compared to regular human insulin, which translates to fewer glycemic spikes after meals 19.

NovoLog is compatible with insulin pump therapy (continuous subcutaneous insulin infusion, or CSII). The JDRF-funded study of CSII in type 1 diabetes (N=485) used rapid-acting analogs including insulin aspart and found a mean A1c improvement of 0.5% over 12 months 20. BCBS plans that cover insulin pumps generally also cover NovoLog for pump use, though separate PA may be required for the pump device itself.

Adverse effects are primarily hypoglycemia and injection-site reactions. The FDA label reports severe hypoglycemia in 7.9% of type 1 patients and 0.8% of type 2 patients over 24 weeks 2. Continuous glucose monitoring (CGM) reduces hypoglycemia risk by 40% to 60% in patients on intensive insulin therapy, according to a meta-analysis of 15 RCTs published in The Lancet (N=2,461) 21. If your BCBS plan covers CGM, using it alongside NovoLog improves safety.

Filing an Appeal if BCBS Denies NovoLog Coverage

If your BCBS plan denies coverage or applies unexpected restrictions, you have the right to appeal. Federal law requires all commercial health plans to provide an internal appeals process and an external review option 22.

The appeal process follows a predictable sequence. First, ask your clinician to submit a letter of medical necessity citing ADA Standards of Care 3 and any patient-specific clinical factors (prior hypoglycemia on alternatives, pump compatibility requirements, documented A1c improvement on NovoLog). Second, file an internal appeal through your BCBS member portal within 180 days of the denial. Third, if the internal appeal is denied, request an external review by an independent review organization. External reviews overturn insurer denials approximately 40% to 60% of the time for medically necessary medications, according to data from the National Association of Insurance Commissioners.

Keep every denial letter and document all phone calls with BCBS representatives, including the date, representative name, and reference number for each call. Your state's department of insurance can also intervene if you believe the denial violates state insulin coverage mandates.